title: Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
abstract: This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS). A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.
authors.affiliation: Uludag University Medical School, Department of Endocrinology and Metabolism, Bursa, Turkey.
authors.forename: Ozen Oz
authors.initials: OO
authors.lastname: Gul
authors.affiliation: Sevket Yilmaz Education and Reserach Hospital, Department of Endocrinology and Metabolism, Bursa, Turkey.
authors.forename: Soner
authors.initials: S
authors.lastname: Cander
authors.affiliation: Sevket Yilmaz Education and Reserach Hospital, Department of Nephrology, Bursa, Turkey.
authors.forename: Bulent
authors.initials: B
authors.lastname: Gul
authors.affiliation: Uludag University Medical School, Department of Biochemistry, Bursa, Turkey.
authors.forename: Ebru
authors.initials: E
authors.lastname: Açıkgoz
authors.affiliation: Uludag University Medical School, Department of Biochemistry, Bursa, Turkey.
authors.forename: Emre
authors.initials: E
authors.lastname: Sarandol
authors.affiliation: Uludag University Medical School, Department of Endocrinology and Metabolism, Bursa, Turkey.
authors.forename: Canan
authors.initials: C
authors.lastname: Ersoy
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D009765:Obesity / Q000097:blood* / Q000150:complications*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications*; D052243:Resistin / Q000097:blood*; D055815:Young Adult
chemical_list: D016207:Cytokines; D007328:Insulin; D008055:Lipids; C499624:RETN protein, human; D052243:Resistin; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human
keywords: insulin resistance; obesity; polycystic ovary syndrome; resistin; visfatin